

28 November 2016

United Greeneries Receives Cannabis Seed Import Permit

- **Import Permit enables United Greeneries to commence cultivation in December**
- **MMJ to provide Canadian consumers with access to one of the largest cannabis catalogues available via simultaneous cultivation of multiple strains**
- **MMJ focused on major expansion opportunity in Canadian medical and future recreational markets, estimated to grow to C\$8b p.a. by 2024**

MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”) is pleased to advise that its Canadian subsidiary, United Greeneries Ltd (“UG”), has received an Import Permit from Health Canada (“HC”) and the Canadian Food Inspection Agency (“CFIA”), allowing for the importation of 1kg of cannabis seeds. Importantly, this will enable UG to commence cultivation activities at the Duncan Facility in December.

The securing of an Import Permit is a significant milestone, as it positions UG as one of a select number of companies operating in the Canadian cannabis market with the capacity to import critical starter material required to grow commercial quantities of cannabis.

Due to international prohibitions on the transport and importation of Cannabis, the availability of legal starter materials has been extremely limited. MMJ’s highly experience team has been able to identify a solution to solve this industry bottle neck, and as a result the Company will be able to provide Canadian consumers with a broad range of cannabis varieties that have not previously legally been available on the Canadian market.

UG will undertake the staged expansion of the Duncan Facility, with initial earmarked production of circa 7,500kg of cannabis by the end of 2018, following the facility’s first full year of production. UG plans to then rapidly scale up the production capacity of the Duncan Facility to circa 60,000kg by 2022.

MMJ PhytoTech’s Managing Director, Andreas Gedeon, commented:

“This is a significant achievement for the Company, as it is one of very few importation licenses to have ever been issued, paving the way for United Greeneries to import an unprecedented range of cannabis genetics into the Canadian market.

This permit ensures the Company is no longer dependent on purchasing limited genetics from other Licensed Producers, and limits the risk of introducing foreign pests and diseases, which can significantly disrupt operational performance.

Importantly, United Greeneries will be able to supply the Canadian market with a variety of cannabis strains that cover the entire spectrum of cannabinoid profiles, including most tastes and flavours the plant has to offer. We believe this will give us a significant marketing advantage when it comes to catering to specific client demands, as we look to position as a first mover in the Canadian recreational market.

ASX RELEASE

United Greeneries is expected to have the material in its possession within the next two weeks and commence growing operations at the Duncan facility in December, with a view to increasing production in Q1 2017.

The Board looks forward to providing shareholders with further updates on the commencement of cultivation at Duncan, and on the Company's TSX-V listing in due course."

-ENDS-

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067



Follow us on Twitter @MMJPhytoTechLtd

<http://www.mmjphytotech.com.au>

About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX. MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

United Greeneries Holding Ltd. has established world-class growing facilities in Canada, including the fully licensed Duncan Facility. MMJ is the first Australian-based company to receive a Canadian medicinal cannabis cultivation licence, and one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.

The Company's European, cannabis-based, pharmaceutical, nutraceutical and cosmetics division operates under its 100% owned subsidiary, **Satipharm AG**. MMJ began production of its Gelpell® Microgel Capsules in May 2015, and is committed to boosting the sales of its flagship product throughout regulated markets globally.



ASX RELEASE

MMJ's Israel-based subsidiary, **PhytoTech Therapeutics Ltd**, is responsible for the Company's R&D activities, with a key focus on the development and commercialisation of new and existing delivery systems and devices that have the potential to deliver safe, effective and measured doses of medicinal cannabis to patients.